Nykode Therapeutics Past Earnings Performance
Past criteria checks 0/6
Nykode Therapeutics's earnings have been declining at an average annual rate of -10.7%, while the Biotechs industry saw earnings growing at 17.9% annually. Revenues have been growing at an average rate of 14.7% per year.
Key information
-10.7%
Earnings growth rate
-13.6%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 14.7% |
| Return on equity | -32.3% |
| Net Margin | -289.4% |
| Next Earnings Update | 28 Feb 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Nykode Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 15 | -42 | 27 | 0 |
| 30 Jun 23 | 13 | -47 | 19 | 0 |
| 31 Mar 23 | 11 | -46 | 24 | 0 |
| 31 Dec 22 | 9 | -43 | 19 | 0 |
| 30 Sep 22 | 38 | -20 | 19 | 0 |
| 30 Jun 22 | 38 | -12 | 11 | 0 |
| 31 Mar 22 | 36 | -10 | 15 | 0 |
| 31 Dec 21 | 36 | -9 | 18 | 0 |
| 30 Sep 21 | 219 | 147 | 19 | 0 |
| 30 Jun 21 | 218 | 146 | 20 | 0 |
| 31 Mar 21 | 216 | 146 | 20 | 0 |
| 31 Dec 20 | 216 | 150 | 16 | 0 |
| 30 Sep 20 | 1 | -24 | 11 | 0 |
| 30 Jun 20 | 1 | -19 | 8 | 0 |
| 31 Mar 20 | 1 | -15 | 6 | 0 |
| 31 Dec 19 | 1 | -14 | 6 | 0 |
| 30 Sep 19 | 1 | -9 | 3 | -3 |
| 30 Jun 19 | 1 | -9 | 3 | -2 |
| 31 Mar 19 | 1 | -8 | 3 | -1 |
| 31 Dec 18 | 1 | -7 | 2 | 0 |
| 30 Sep 18 | 2 | -7 | 2 | 2 |
| 30 Jun 18 | 1 | -5 | 2 | 1 |
| 31 Mar 18 | 1 | -5 | 2 | 1 |
| 31 Dec 17 | 1 | -4 | 2 | 0 |
Quality Earnings: NYKDO is currently unprofitable.
Growing Profit Margin: NYKDO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NYKDO is unprofitable, and losses have increased over the past 5 years at a rate of 10.7% per year.
Accelerating Growth: Unable to compare NYKDO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NYKDO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29.6%).
Return on Equity
High ROE: NYKDO has a negative Return on Equity (-32.25%), as it is currently unprofitable.